Study in Mice Shows Promise for Resveratrol in Ovarian Cancer

Article

A mouse study found that resveratrol has a significant antitumor effect in an ovarian cancer model, and also suppressed tumor regrowth following cisplatin.

A mouse study found that resveratrol has a significant antitumor effect in an ovarian cancer model. The molecule also suppressed tumor regrowth following treatment with cisplatin, suggesting it could be used to prolong disease-free survival if confirmed in human ovarian cancer patients.

“We have found that although resveratrol can induce apoptotic cell death, it can also induce autophagocytic cell death, and inhibits glucose uptake in ovarian cancer cells in vitro,” wrote J. Rebecca Liu, MD, of the University of Michigan Health System in Ann Arbor, and colleagues. “We hypothesized that because resveratrol can induce cell death through a mechanism distinct from apoptosis, it may provide a therapeutic advantage in the management of chemoresistant ovarian cancer.”

The researchers used a fluorescent xenograft mouse model of ovarian cancer. The mice were treated with cisplatin, resveratrol, or vehicle control, and were assessed using whole-body imaging, micro-positron emission tomography, and transmission electron microscopy for resected tissue. The results of the study were published in Cancer.

Both cisplatin and resveratrol resulted in significantly smaller tumors than in the control mice. This was true for both drugs at 17 days (P = .0007 for cisplatin vs control; P = .0003 for resveratrol vs control) and at 21 days (P = .0002 and P = .001, respectively). There were no significant differences between the cisplatin- and resveratrol-treated mice.

In another set of mice with ovarian cancer, cisplatin was administered but then withdrawn before complete regression of the tumor was observed. Resveratrol administered at that point resulted in reduced tumor regrowth compared with control mice, at days 16 (P = .008), 23 (P = .011), and 25 (P = .005).

The study also found that resveratrol yielded a marked decrease in tumor uptake of glucose compared with controls, and resected tissue showed induction of autophagy in the resveratrol-treated tumors.

“The results of the current study demonstrate that resveratrol has significant antineoplastic activity and suppresses glucose metabolism in a xenograft mouse model of ovarian carcinoma,” the authors concluded. “These properties suggest that resveratrol, and compounds similar to this phytoalexin, have therapeutic potential in the treatment of epithelial ovarian carcinoma.”

Recent Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Related Content